AU5440799A - Method and drug for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty - Google Patents

Method and drug for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty

Info

Publication number
AU5440799A
AU5440799A AU54407/99A AU5440799A AU5440799A AU 5440799 A AU5440799 A AU 5440799A AU 54407/99 A AU54407/99 A AU 54407/99A AU 5440799 A AU5440799 A AU 5440799A AU 5440799 A AU5440799 A AU 5440799A
Authority
AU
Australia
Prior art keywords
restenosis
drug
prevention
treatment
heart disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54407/99A
Inventor
Guido Schnyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5440799A publication Critical patent/AU5440799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU54407/99A 1998-09-17 1999-09-14 Method and drug for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty Abandoned AU5440799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WO801444 1998-09-17
IB9801444 1998-09-17
PCT/IB1999/001545 WO2000016759A2 (en) 1998-09-17 1999-09-14 Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty

Publications (1)

Publication Number Publication Date
AU5440799A true AU5440799A (en) 2000-04-10

Family

ID=11004753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54407/99A Abandoned AU5440799A (en) 1998-09-17 1999-09-14 Method and drug for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty

Country Status (2)

Country Link
AU (1) AU5440799A (en)
WO (1) WO2000016759A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006200292B2 (en) * 2001-03-16 2007-11-22 Novogen Research Pty Ltd Treatment of restenosis
WO2002074307A1 (en) * 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
AU2008200518B2 (en) * 2001-03-16 2010-04-01 Novogen Research Pty Ltd Treatment of restenosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1477178A3 (en) * 1992-05-19 2005-02-16 KELLY, Graham Edmund Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US5516528A (en) * 1995-01-13 1996-05-14 Wake Forest University Dietary phytoestrogen in estrogen replacement therapy
JP3476604B2 (en) * 1995-08-22 2003-12-10 鐘淵化学工業株式会社 Method for manufacturing stent with drug attached / coated
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector

Also Published As

Publication number Publication date
WO2000016759A2 (en) 2000-03-30
WO2000016759A3 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
AU7628500A (en) Dilatation/centering catheter for the treatment of stenosis
AU3241099A (en) Angioplasty and stent delivery catheter
AU7913800A (en) Catheter for carrying out the combined examination of the left ventricle and of the right and left coronary arteries
AU6198490A (en) An expandable transluminal atherectomy catheter system and method for the treatment of arterial stenoses
AU2001276952A1 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU8661998A (en) Cryotherapy method for reducing tissue injury after balloon angioplasty or stentimplantation
AU7727591A (en) Method for preventing onset of restenosis after angioplasty employing pravastatin
GB2347685B (en) NiTi-based medical guidewire and method of producing the same
AU1724099A (en) Vascular stent for reduction of restenosis
AU7053494A (en) Method of treating coronary vascular disease using docosahexaenoic acid
EP1022945A4 (en) Method and formulation for treating vascular disease
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
AU7091900A (en) Coating having biological activity and medical implant having surface carrying the same and method
AU5056300A (en) Devices and compounds for treating arterial restenosis
AU1025199A (en) Coated medical implants, method for producing them, and use of the same for preventing restenosis
ZA988016B (en) Compounds methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
EP1191941A4 (en) A method for the prophylaxis and/or treatment of medical disorders
DE69215954D1 (en) Angioplasty catheter and its manufacturing process
AU5537994A (en) Therapeutic treatment for inhibiting vascular restenosis
AU6914296A (en) Left coronary artery catheter
AU4069095A (en) Medicaments for the treatment of restenosis and arterial sclerosis
AU9016898A (en) Methods and compositions for treatment of restenosis
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
EP1018965A4 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU3142400A (en) A pharmaceutical composition for treating angiocardiopathy and the method of producing thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase